Therefore, since 2009, Danish guidelines have recommended systematic screening by interferon gamma release assays (IGRA) for TBI regardless of exposure to M. tuberculosis before initiation of biological agents to treat inflammatory bowel disease (IBD) and rheumatic disease (IRD) [11]. This evidence concerns the gene IFNG and inflammatory bowel disease.